MERCURY Clinical Study (AIH)

What is the Purpose of the MERCURY Study?

The MERCURY Study looks to understand the safety and efficacy of a study drug in adults with autoimmune hepatitis who have not responded or cannot tolerate the current AIH standard of care.

Can I Participate?

You may be eligible to participate in this study if you:  

Are 18 to 75 years old  

Have been diagnosed with autoimmune hepatitis (AIH) 

Have not responded well or cannot tolerate your current standard therapies for AIH   

Other eligibility criteria apply and will be evaluated and finalized by a study doctor if you choose to continue with screening for the study.  

Learn More

Why Should I Join the MERCURY Study?

If you’re unable to achieve remission or cannot tolerate your current treatments for AIH, this study is looking to better understand if a study drug may potentially reduce the need for long-term use of steroids for AIH.

What You Should Know About This Study

There is no cost for you to participate in this study. 

Eligible participants may receive reasonable reimbursement for travel-related expenses.  

Both groups continue to receive background therapies for their AIH in addition to the study drug.  

The study drug or placebo is given 3 times over the course of a year during the treatment period.

After completion of the treatment period, eligible participants will be able to receive the study drug during the optional open-label period.

What Should I Expect?

fill out the questionnaire

Open-Label Period  

This study also has an optional open-label period at the conclusion of the treatment period. Open-label means the placebo is removed, and both you and the study team know you’re receiving the study drug.

Eligible participants who complete the treatment period will be able to receive the study drug 5 times over 2 years following the treatment period if they choose to participate.

Submit Online Questionnaire

This questionnaire will ask for your contact information and a few questions about your medical history to determine your eligibility.

Then, select a time for a short phone call with PatientWing. Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.

Speak With PatientWing

PatientWing is helping to identify potential participants who may be interested in the MERCURY study. You will have a short call with PatientWing to answer additional questions about your medical history. 

Study Participation

After you've completed the screening period, the study team will notify you about your eligibility. 

If you are eligible to move forward, you will be asked to review and sign an informed consent form. This consent is voluntary, and you may withdraw it and stop participating in the trial at any time. 

If you are enrolled in the study, you should expect the following:  

Study participation lasts up to 32 months including the treatment and safety follow-up periods.  

You will be randomly assigned to receive either the study drug or the placebo 3 times over the course of a year during the treatment period  

You will have 18 visits during the treatment period and have the opportunity for 5 of those visits to be home visits.  

There is no cost for you to participate in this study. Reasonable expenses such as travel and parking may be reimbursed.  

Speak With A Research Site

If the PatientWing team has determined you are initially eligible for the MERCURY Study, you will meet the study team at the research site who will review your medical records.  

If the study team thinks you are a good fit, they will schedule a screening visit. 

The study team will provide more information during your conversations with them. No question is a bad question, so please share any questions or comments about the study with the team! 

Frequently Asked Questions

How is PatientWing involved in this clinical study process?

We partner with study sponsors to match individuals with clinical studies. Our dedicated team provides clear information about available studies, connects you with research sites, and ensures you have the resources and guidance you needat every step. We are here to support your journey with clinical research!

How do I get started?

Complete the questionnaire and enter your information to express interest in the study. You can also:
email studies@patientwing.com or call 213-459-2979.

How will the study drug be taken?  

The study drug or placebo will be given 3 times over the 52-week treatment period. The study drug also has the option of being given 5 times during the optional open-label period, if you are eligible and choose toparticipate.   

How often do I need to visit the research site?  

You will have 21 visits with the study team during the treatment and safety follow-up periods. Some of the visits during the treatment period may have the option of being conducted at home.  
There will be an additional 14 visits with the study team during the optional open-label period if you are eligible and choose to participate.  

Is there a chance I will receive a placebo?

Yes, this study has a 50% chance of receiving a placebo. A placebo will look and be administered just like the study drug but will contain no active ingredients. Following the treatment period, the placebo will be removed during the optional open-label period, and all eligible patients who completed the treatment period will be able to receive the study drug.

Will I receive compensation if I participate in this study?  

No, compensation is not provided for participating in this study. However, you may be reimbursed for any travel expenses related to your study visits. The study coordinator can provide you with specific information regarding reimbursement. 

Can I leave the study at any time?  

You’re free to withdraw from the study at any time as study participation is completely voluntary. Withdrawal will not be used against you nor affect your standard medical care in any way. Please contact the study doctor so that they can safely withdraw your participation in the study. 

Even When One Path Doesn't Work, There May Still Be A Way Forward

Frequently Asked Questions